Spinomix has a new CEO and a new Chairman of the Board

Spinomix, a Swiss life sciences company, is focused on becoming a leader in providing solutions for improved molecular and conventional diagnostics, as well as analytical products. These two appointments exemplify the strategic direction and forward momentum of the company. Earlier this year, Spinomix announced the closing of a Series A equity investment of $3 million (USD).

“Spinomix is very fortunate to have Dr. Pietro Scalfaro as the Company CEO,” said the newly appointed Chairman of the Spinomix Board of Directors, Heiner Dreismann, PhD “Scalfaro’s broad industry and clinical experience, combined with his knowledge and success working with diagnostic start-up companies, makes him an ideal candidate to lead Spinomix into its next phase of development.”

Pietro Scalfaro, MD, MBA – Scalfaro brings Spinomix nearly 25 years of combined clinical practice and business acumen. Over the course of his 10-year tenure at Debiopharm, where he served as Chief Project Officer, Scalfaro led several successful drug development programs and implemented the Portfolio and Personalized Medicine Strategy – a streamlined approach covering all relevant pharmaceutical functions across 15 programs at different stages of development. Scalfaro holds an MD in gastroenterology and is a specialist in intensive care pediatrics. He received an executive Masters of Business Administration (MBA) in corporate finance from the University of Lausanne.

Scalfaro also has significant experience leading private equity investments for start-up molecular diagnostic companies focused on personalized medicine. He has served on the boards of Agendia, Biocartis, Diagnoplex SA, and Immunexpress.

“With our team’s expertise and the unique technologies – MagPhase and FibroTrap – Spinomix has the potential to improve patient outcomes by providing new diagnostic solutions that meet a real need and provide answers for healthcare professionals with accuracy and speed,” said Pietro Scalfaro, MD, MBA, Chief Executive Office, Spinomix.

Heiner Dreismann, PhD – Dreismann is a pioneer of the polymerase chain reaction (PCR) technique and a seasoned executive with more than 30 years of experience in the healthcare industry. As the former President and CEO of Roche Molecular Systems, Dreismann is a well-recognized leader within the diagnostic community. During his tenure as CEO of Roche Molecular Systems, annual sales increased strongly and the portfolio of tests and hardware sales doubled in size.

Dreismann currently serves on the boards of a number of high-technology companies including Magellan BioSciences, MedBioGene, Myriad Genetics, and Singulex.

“It is a privilege to join Spinomix at this stage of its development,” said Dreismann. “Spinomix is well-positioned to make important contributions to the diagnostic and broader healthcare community through the more sensitive identification of disease targets that could ultimately increase the speed and accuracy of treatment for patients with certain diseases.”

About Spinomix SA

Spinomix SA is a life sciences company committed to developing cost-effective easy-to-use diagnostic products that offer quality results with high speed. Spinomix’ core competencies are in the development of fully-automated and miniaturized instruments and reagents that allow for improved extraction, manipulation, and detection of biochemical substances. The Company’s two leading technologies combine advanced magnetics nanoparticles handling technology and microfluidics: MagPhase, an automated magnetic nanoparticles sample preparation platform intended to improve the mature bead technology and FibroTrap, a fibrinogen chemistry based technology that separates targets within a simple routine sample collection tube.

Spinomix was founded in 2004 and is located at the Swiss Federal Institute of Technology of Lausanne (EPFL), Lausanne. The company was awarded several prizes, e.g. the award of the W. A. de Vigier Foundation and the CTI Start-up Label.